Cumberland Pharmaceuticals Inc. CPIX
Set alert
At close · Oct 30
After hours · Oct 30, 5:49 PM ET
- YTD
- +17.84%
- 1 year
- +46.11%
- Open
- 4.35
- Prev close
- 4.35
- Mkt cap
- 70.27M
- Vol
- 128.96K
- Avg vol
- 84.11K
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.35
- High
- 4.76
- Forward P/E
- 16.07
- Beta
- 0.22
- Short ratio
- 0.92
- Inst. own
- 14.69%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.40
- 200-d avg
- 1.48
- 1y target
- 0.00
5D chart
Signals (65)
| Name | Time | Ago |
|---|---|---|
| RSI: Oversold | Oct 29, 3:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 12:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 28, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:00 AM | 4 days ago |
| RSI: Oversold | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 1:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 12:45 PM | 5 days ago |
| RSI: Oversold | Oct 26, 12:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 11:40 AM | 5 days ago |
| RSI: Oversold | Oct 26, 10:10 AM | 5 days ago |
| RSI: Oversold | Oct 26, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 26, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 23, 3:50 PM | 1 week ago |
Key statistics
- Market cap
- 31.60M
- Enterprise value
- 35.51M
- Trailing P/E
- 0.00
- Forward P/E
- 16.07
- PEG ratio
- 0.00
- Price / sales
- 0.86
- Price / book
- 1.27
- EPS (TTM)
- -0.76
- Beta
- 0.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -29.55%
- Revenue (TTM)
- 36.79M
- Revenue growth
- -9.90%
- Free cash flow
- 3.91M
- Total cash
- 17.46M
- Total debt
- 21.48M
- Return on equity
- -36.07%
- Shares outstanding
- 14.04M
- Short % of float
- 2.09%
- 50-day average
- 1.40
- 200-day average
- 1.48
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -0.02 | — | — |
| Aug 6, 2024 | Jun 1, 2024 | 0.00 | 0.01 | — | — |
| May 7, 2024 | Mar 1, 2024 | 0.00 | -0.05 | — | — |
| Mar 5, 2024 | Dec 1, 2023 | 0.00 | -0.11 | — | — |
| Nov 7, 2023 | Sep 1, 2023 | 0.00 | 0.02 | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | 0.16 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 3, 2019 | B. Riley Securities | main | — | Buy |
| Nov 18, 2019 | B. Riley Securities | main | — | Buy |
| Aug 17, 2018 | B. Riley Securities | main | Buy | Buy |
| Apr 17, 2018 | B. Riley Securities | init | — | Buy |
| Apr 10, 2013 | UBS | main | — | Neutral |
| Nov 12, 2012 | UBS | main | — | Neutral |
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- cumberlandpharma.com
News
- Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript
- Cumberland Pharmaceuticals Begins Rolling FDA NDA for Dyscorban in Duchenne Cardiomyopathy
- 12 Health Care Stocks Moving In Monday's After-Market Session
- Cumberland Pharmaceuticals Intends To File New Drug Application To FDA For Ifetroban To Treat Cardiomyopathy Associated With Duchenne Muscular Dystrophy
- CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Cumberland Pharmaceuticals Announces Data From Its Phase 2 ASSIST-SSc Study Of Oral Ifetroban For Patients With Systemic Sclerosis; Gastrointestinal Adverse Events Were More Frequent In Ifetroban Group Than Placebo; Majority Of Patients Demonstrated Limited Disease Progression, Which Reduced Ability To Track Treatment Difference
- Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results
- CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL
Your note
Sign in to keep a note on CPIX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN MARTIN S JR | Director | Stock Award(Grant) | Mar 24, 2024 | 6,000 |
| GALANTE JOSEPH C. | Director | Stock Award(Grant) | Mar 24, 2024 | 59,356 |
| JONES JAMES R | Director | Purchase | Nov 28, 2024 | 39,377 |
| KAZIMI A. J. | Chief Executive Officer | Purchase | Nov 28, 2024 | 5,701,530 |
| KROGULSKI KENNETH J | Director | Purchase | Nov 28, 2024 | 271,627 |
| YOUNG CAROLINE R | Director | Purchase | Nov 28, 2024 | 29,664 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 3.76% | 528,163 | 1.19M | Sep 29, 2024 |
| Vanguard Group Inc | 2.67% | 374,251 | 842.06K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 2.04% | 286,655 | 644.97K | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 2.02% | 284,005 | 639.01K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.34% | 188,164 | 423.37K | Sep 29, 2024 |
| Blackrock Inc. | 0.78% | 110,068 | 247.65K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.00% | 280,820 | 631.85K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 1.66% | 233,068 | 524.40K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.60% | 84,244 | 189.55K | Sep 29, 2024 |
| DFA U.S. Targeted Value Portfolio | 0.57% | 79,720 | 179.37K | Jul 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.36% | 49,887 | 112.25K | Sep 29, 2024 |
| DFA U.S. Micro Cap Series | 0.34% | 47,772 | 107.49K | Jul 30, 2024 |